Immutep (IMM) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Strategic positioning and pipeline highlights

• Focus on pioneering LAG-3 immunotherapy, with a robust pipeline in immuno-oncology and autoimmune diseases.

• Eftilagimod alpha (efti) is a first-in-class MHC Class II agonist, activating antigen-presenting cells for unique immune modulation.

• IMP761, targeting autoimmune diseases, has entered clinical stage with first subject dosed and initial data expected before year-end.

• Company is well-funded through end of 2026 and collaborates with major pharmaceutical partners.

• Multiple late-stage and ongoing trials in lung, head and neck, breast, sarcoma, and urothelial cancers.

Clinical trial progress and efficacy data

• TACTI-002/KEYNOTE-798 trial in first-line non-small cell lung cancer (NSCLC) showed outstanding efficacy and safety, with strong overall survival and response rates.

• INSIGHT-003 trial combining efti, KEYTRUDA, and chemotherapy demonstrated a 70% overall response rate, with encouraging PFS and OS.

• Phase III TACTI-004 trial in NSCLC, in collaboration with Merck, will enroll ~750 patients globally, with dual primary endpoints and interim/futility analyses planned for 2025–2026.

• TACTI-003 head and neck cancer trial showed high response rates, especially in CPS <1 patients, with deep, durable responses and strong safety profile.

• Metastatic breast cancer and other indications are in late-stage or ongoing trials, with new data expected before year-end.

Mechanism of action and differentiation

• Eftilagimod is not an anti-LAG-3; it uses LAG-3 as a tool to activate APCs, unlike other checkpoint inhibitors.

• Demonstrates synergistic effects with anti-PD-1 therapies by enhancing immune cell activation and tumor infiltration.

• Efti’s efficacy is independent of TPS/CPS biomarker status, broadening its potential patient impact.